Myeloid Therapeutics is developing a vaccine to address the COVID-19 pandemic

COVID-19 ATAK™ Vaccine Roadmap

An ATAK™ Approach for

SARS-CoV-2

Virus

Myeloid cell: CD14

T cell

Unlocking T cells for Long-term Immunity & Protection from COVID-19

Historically prophylactic viral vaccines have concentrated on the stimulation of neutralizing antibodies. Many have failed to induce long-term efficacy and protection.


Approaches that activate T cells may overcome this.

ATAK™

in action

T cell vaccines

 

Myeloid Vaccine Clinical Programs

Killed virus

COVID-19 ATAK™

Myeloid Cell Vaccine

Prior studies of SARS-CoV-1 and MERS strongly support testing of alternative strategies capable of eliciting SARS-CoV-2-specific

T cell responses.

The current COVID-19 landscape has observed the emergence of vaccines that focus on the generation of neutralizing antibodies.  While these efforts are justified, prior studies of SARS-CoV-1 and MERS strongly support testing of alternative strategies capable of eliciting SARS-CoV-2-specific T cell responses.  It has been shown that T cell immunity is protective for SARS-CoV and plays an important role in recovery from infection.  Suboptimal T cell responses also contribute to the development of severe SARS in animal models, which may explain the high mortality of SARS-CoV-2 in the elderly.  In SARS-CoV, cellular immunity may also offer longer protection than antibodies.  In patients who have recovered from SARS-CoV infection, anti-viral antibodies are often undetectable, whereas memory T cells have been shown to persist for up to 6 years. In addition, it is possible that the induction of anti-SARS-CoV-2 Abs will increase disease severity. 

 

Multiple studies have suggested that Antibody Dependent Enhancement (ADE) of coronavirus infections occur and, in SARS-CoV/macaque models, anti-S protein IgG has been shown to exacerbate Acute Lung Injury (ALI). For these reasons, it has been suggested that vaccines against emerging coronaviruses should emphasize the generation of a memory CD8+ T cell response.  Based on our work with glioblastoma,  we have developed a novel SARS-CoV-2 T cell vaccine, referred to as the COVID-19 ATAK™ myeloid cell vaccine.

 
 

COVID-19 ATAK™ Programs

Our ATAK™ (Activate Target Attack Kill) vaccine platform enables myeloid cells to stimulate an immune response to viruses and cancers.  ATAK™ myeloid cells sustain the ability to cross-present antigen, thereby generating a durable anti-tumor and anti-viral response by cytotoxic T cells.

 

In preclinical studies of glioblastoma the ATAK™ vaccine demonstrated a reduction in tumor burden.

Programs & Pipeline

DISCOVERY

LEAD OPTIMIZATION

IND ENABLING

CLINICAL DOSING

MT-201

CMV-ATAK™ Cells

Glioblastoma

MT-202

COVID-19 ATAK™

Healthy Adults

 

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139